Page last updated: 2024-12-05

lypressin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Lypressin: The porcine antidiuretic hormone (VASOPRESSINS). It is a cyclic nonapeptide that differs from ARG-VASOPRESSIN by one amino acid, containing a LYSINE at residue 8 instead of an ARGININE. Lys-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID644076
CHEMBL ID1200690
CHEBI ID94802
SCHEMBL ID33287
MeSH IDM0012831

Synonyms (86)

Synonym
[lys8]avp
(2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)1,2-dithia-5,8,11,14,17-pentazacycl
gtpl2172
l-8
diapid
l-lysine vasopressin
lysine pitressin
syntopressin
cys-tyr-phe-gln-asn-cys-pro-lys-gly-nh2[disulfide bridge: 1-6]
vasopressin, 8-l-lysine- (7ci,8ci,9ci)
l-lysinamide,
1-[[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentaazacycloeicos-4-y
1,2-dithia-5,8,11,14,17-pentaazacycloeicosane-10-propionamide
vasopressin (lysine form)
vasopressin, 8-l-lysine-
lysipressin
[8-lysine]vasopressin
lysine vasopressin
lysylvasopressin
l-cysteinyl-l-tyrosyl-l-phenylalanyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-lysylglycinamide cyclic (1->6)-disulfide
glycinamide, l-cysteinyl-l-tyrosyl-l-phenylalanyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-lysyl-, cyclic (1>6)-disulfide
vasopressin-8-lysine
8-l-lysinevasopressin
l]carbonyl]-l-prolyl-n-(2-amino-2-oxoethyl)-
postacton
l 8
lysopressin
oxytocin, 3-(l-phenylalanine)-8-l-lysine-
lysine-adh
19-amino-4-[2-[[5-amino-1-[(carbamoylmethyl)carbamoyl]pentyl]carbamoyl]-1-pyrrolidinylcarbonyl]-13-benzyl-7-(carbamoylmethyl)-16-p-hydroxybenzyl-6,9,12,15,18-pentaoxo- (6ci)
lypressin
lysyl vasopressin
vasopressin, lysine
brn 4648365
einecs 200-050-5
(8-lysine)vasopressin
lipresina [inn-spanish]
lypressinum [inn-latin]
lypressine [inn-french]
lipressina [dcit]
lysine-vasopressin
l-cysteinyl-l-tyrosyl-l-phenylalanyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-lysylglycinamide cyclic (1-6)-disulfide
vasopressin, 8-l-lysine
CHEMBL1200690
vasopressin pig
(2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan
8 lysine vasopressin
cys-tyr-phe-gln-asn-cys-pro-lys-gly-nh2, cyclic 1-6 disulfide
lys vasopressin
8-lysine vasopressin
vasopressin, lysyl
vasopressin, 8-lysine
cas-50-57-7
tox21_113427
dtxcid8028501
dtxsid8048575 ,
tox21_112902
lipresina
7czf3l922y ,
lypressin [usan:usp:inn:ban]
lypressine
lipressina
unii-7czf3l922y
lypressinum
BRD-K93331255-001-01-2
SCHEMBL33287
HY-P0004
CS-5838
AKOS030529559
(2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacy
CHEBI:94802
mfcd00076754
1-{[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-l-p rolyl-l-lysylglycinamide
l-cysteinyl-l-tyrosyl-l-phenylalanyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-lysylglycinamide cyclic (1->6)-disulphide
DB14642
BJFIDCADFRDPIO-DZCXQCEKSA-N
Q27082434
(s)-n-((s)-6-amino-1-((2-amino-2-oxoethyl)amino)-1-oxohexan-2-yl)-1-((4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbo
50-57-7 (free base)
CCG-270620
C75370
[lys8]-vasopressinlysine vasopressin
lypressin (mart.)
h01ba03
lypressin (usp-rs)
lypressin (usp impurity)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Terlipressin associated with albumin appears to be a safe and effective treatment of hepatorenal syndrome."( Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.
Arroyo, V; Bataller, R; Cárdenas, A; Ginès, P; Jiménez, W; Mas, A; Navasa, M; Rodés, J; Salmerón, JM; Sort, P; Uriz, J, 2000
)
0.31
"Terlipressin and Gelatinepolysuccinat appear to be a safe and effective treatment of hepatorenal syndrome."( Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
Biglarnia, R; Broelsch, CE; Frühauf, NR; Kavuk, I; Lang, H; Malagó, M; Saner, F; Schäfers, RF, 2004
)
0.32
"The study confirms that administration of terlipressin, by either Haemopressin or Glypressin, is generally safe and indeed highly effective in the treatment of acute EVH."( Open, randomized, comparative study of efficacy and safety between Haemopressin and Glypressin in treating acute esophageal varices hemorrhage.
Hu, RH; Lee, PH,
)
0.13
" Adverse events are mostly cardiovascular and related to vasoconstriction."( Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Bendtsen, F; Borup, T; Krag, A; Møller, S, 2008
)
0.35
" Complication of congestive heart failure possibly related to this regimen was seen in 1 patient, but ischemic adverse events were not observed during the treatment."( The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
Fukui, H; Kanazawa, H; Kokubu, S; Maruyama, H; Masaki, N; Matsuzaki, Y; Mochida, S; Narahara, Y; Okita, K; Sakamoto, C; Sumino, Y; Uemura, M; Yokosuka, O, 2012
)
0.38
" Therefore, the possible benefits of terlipressin should be always weighed against potential severe adverse effects."( Safety and Efficacy of Terlipressin in Pediatric Distributive Shock: A Retrospective Analysis in 20 Children.
Hofbeck, M; Kumpf, M; Michel, J; Neunhoeffer, F; Renk, H; Spiller, G, 2017
)
0.46
" It is a safe drug with mild secondary effects."( Cutaneous necrosis secondary to terlipressin therapy. A rare but serious side effect. Case report and literature review.
Badía Aranda, E; Bernad Cabredo, B; Corrales Cruz, D; Iglesias Julián, E; Romero Arauzo, MJ, 2017
)
0.46
" Adverse events, effects of treatment on renal function, model for end-stage liver disease (MELD) score, and paracentesis/thoracentesis requirements were assessed."( Safety and efficacy of outpatient continuous terlipressin infusion for the treatment of portal hypertensive complications in cirrhosis.
Angus, PW; Chapman, B; Gow, PJ; Sinclair, M; Terbah, R; Testro, AG; Thwaites, PA, 2022
)
0.72
" There were no cardiac or ischemic complications and no serious adverse events reported."( Safety and efficacy of outpatient continuous terlipressin infusion for the treatment of portal hypertensive complications in cirrhosis.
Angus, PW; Chapman, B; Gow, PJ; Sinclair, M; Terbah, R; Testro, AG; Thwaites, PA, 2022
)
0.72
"Transplant-eligible and otherwise stable patients can be managed with CTI at home for an extended duration under supervision without adverse consequences."( Safety and efficacy of outpatient continuous terlipressin infusion for the treatment of portal hypertensive complications in cirrhosis.
Angus, PW; Chapman, B; Gow, PJ; Sinclair, M; Terbah, R; Testro, AG; Thwaites, PA, 2022
)
0.72
" Our secondary outcomes will include (1) major neurosensory abnormality and (2) the occurrence of adverse events."( Efficacy and safety of vasopressin and terlipressin in preterm neonates: a protocol for a systematic review.
Alsaadi, AS; Bui, V; Razak, A; Samiee-Zafarghandy, S; Sushko, K; Van Den Anker, J, 2021
)
0.62
"Terlipressin with albumin, the recommended treatment for hepatorenal syndrome-acute kidney injury (HRS-AKI), is associated with adverse events."( Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study.
Gupta, R; Kulkarni, AV; Kumar, K; Premkumar, M; Rao, PN; Ravikumar, ST; Reddy, DN; Sharma, M; Tevethia, H, 2022
)
0.72
" This is a case report of a cirrhotic patient with nonvariceal upper gastrointestinal bleeding after duodenal necrosis due to the use of terlipressin, a novel side effect not yet described in literature to the best of our knowledge."( Duodenal Necrosis and Nonvariceal Digestive Bleeding After Terlipressin Administration for Treatment of Hepatorenal Syndrome: a Case Report of a Novel Side Effect of a Commonly Used Drug.
Andraus, W; Arantes, RM; Carneiro-D'albuquerque, LA; Cunha, MR; De Moura, EG; Ducatti, L; Ernani, L; Fernandes, MR; Galvão, FH; Martino, RB; Nacif, LS; Pereira, PB; Pinheiro, RS; Rocha-Santos, V; Waisberg, DR, 2022
)
0.72
" Given its fatality potential, this novel side effect should be remembered when using this medication in cirrhotic patients."( Duodenal Necrosis and Nonvariceal Digestive Bleeding After Terlipressin Administration for Treatment of Hepatorenal Syndrome: a Case Report of a Novel Side Effect of a Commonly Used Drug.
Andraus, W; Arantes, RM; Carneiro-D'albuquerque, LA; Cunha, MR; De Moura, EG; Ducatti, L; Ernani, L; Fernandes, MR; Galvão, FH; Martino, RB; Nacif, LS; Pereira, PB; Pinheiro, RS; Rocha-Santos, V; Waisberg, DR, 2022
)
0.72
" Hyponatremia was the most frequently reported adverse event (n = 37, 25%)."( Efficacy and Safety of Vasopressin and Terlipressin in Preterm Neonates: A Systematic Review.
Al-Saadi, A; Bui, V; Razak, A; Samiee-Zafarghandy, S; Sushko, K; van den Anker, J, 2022
)
0.72
" This approach in cirrhosis patients with acute esophageal variceal bleed was investigated by comparing the efficacy and adverse events of continuous versus bolus administration of terlipressin."( Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding.
Arora, V; Choudhary, SP; Jindal, A; Kumar, G; Maiwall, R; Sarin, SK; Vijayaraghavan, R, 2023
)
0.91
"001)} and adverse events were fewer {20/55(36."( Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding.
Arora, V; Choudhary, SP; Jindal, A; Kumar, G; Maiwall, R; Sarin, SK; Vijayaraghavan, R, 2023
)
0.91
""HVPG-tailored" continuous terlipressin infusion is more effective than bolus administration in reducing HVPG at a lower dose with fewer adverse events in cirrhotic patients."( Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding.
Arora, V; Choudhary, SP; Jindal, A; Kumar, G; Maiwall, R; Sarin, SK; Vijayaraghavan, R, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" The half-life of distribution and elimination was 8 and 50 min, respectively."( Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers.
Berling, R; Lindblom, P; Nilsson, G; Ohlin, M; Vernersson, E, 1990
)
0.28
"The antianginal and hypotensive activity and the pharmacokinetic properties of glyceryl 1-nitrate (G-1-N) were examined in the rat and in the dog."( [Hypotensive, antianginal action and pharmacokinetics of glyceryl-1-nitrate in rats and dogs].
Laufen, H; Leitold, M; Yeates, RA, 1986
)
0.27
" The half-life of elimination of G-2-N in the rat came to 2 h, and the substance was 100% bioavailable."( [The pharmacology and pharmacokinetics of glycerol-2-nitrate].
Laufen, H; Leitold, M; Yeates, RA, 1987
)
0.27
"The effect of isosorbide 2-mononitrate (IS-2-MN) was compared with that of isosorbide dinitrate (ISDN) in rats regarding the antianginal, haemodynamic and pharmacokinetic properties."( [Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat].
Laufen, H; Leitold, M, 1983
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
" CRH combined with lysine vasopressin or a less pyrogenic IL-1 beta analog, when administered to these rats, accelerated the recovery of the pituitary and the adrenocortical functions significantly, suggesting the potential clinical usefulness of these peptides."( Effects of repetitive administration of recombinant human interleukin-1 beta, an analog or corticotropin-releasing hormone combined with lysine vasopressin on rats with glucocorticoid-induced secondary adrenocortical insufficiency.
Fukata, J; Imura, H; Masui, Y; Murakami, N; Naito, Y; Nakai, Y; Nakao, K; Tominaga, T; Usui, T, 1992
)
0.28
" The aim of this study was to examine the systemic and splanchnic hemodynamic responses to terlipressin administered alone or combined with nitroglycerin in patients with cirrhosis."( [Hemodynamic effects of the administration of terlipressin alone or combined with nitroglycerin in patients with cirrhosis].
Gaudin, C; Hadengue, A; Kleber, G; Lebrec, D; Moreau, R; Sogni, P; Soubrane, O, 1992
)
0.28
"Objective: The objective of this study was to provide an in-depth analysis of the advantages and potential research directions concerning the utilization of terlipressin (TP) in combination with norepinephrine (NE) for the management of septic shock."( TERLIPRESSIN COMBINED WITH NOREPINEPHRINE IN THE TREATMENT OF SEPTIC SHOCK: A SYSTEMATIC REVIEW.
Liang, D; Lin, L; Mao, F; Tang, Z; Xu, Y, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
"The Ussing chamber technique was used as an oral absorption model for studies of the relative effects of the inhibition of enzymatic degradation and increased paracellular route on the transport of the poorly absorbed vasopressin analogues lysine vasopressin (LVP) and desmopressin (DDAVP)."( Effects of enzymatic inhibition and increased paracellular shunting on transport of vasopressin analogues in the rat.
Andreasson, A; Lundin, K; Ungell, AL; Utter, L, 1992
)
0.28
" The bioavailability of G-1-N in the rat and in the dog is practically 100%."( [Hypotensive, antianginal action and pharmacokinetics of glyceryl-1-nitrate in rats and dogs].
Laufen, H; Leitold, M; Yeates, RA, 1986
)
0.27
" The bioavailability of IS-2-MN in the rat was 100%."( [Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat].
Laufen, H; Leitold, M, 1983
)
0.27
" The objectives of this study were to describe the pharmacokinetic behaviour of sodium meclofenamate after intravenous and oral administration to sheep and to determine the influence of closure of the reticular groove on the bioavailability of the drug."( Influence of closure of the reticular groove on the bioavailability and disposition kinetics of meclofenamate in sheep.
Boggio, JC; Encinas, T; Rodríguez, C; San Andrés, MD; San Andrés, MI; Vinagre, E, 1996
)
0.29
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Following low dosage cyproterone acetate (CA) therapy (mean daily dosage 65 mg/m2BSA) a beneficial effect on growth and skeletal maturation was observed."( Effect of cyproterone acetate (CA) on growth and endocrine function in precocious puberty.
Ilicki, A; Stahnke, N; Willig, RP, 1979
)
0.26
" Vasotocin was the most active of the compounds studied and, unlike the vasopressins, its dose-response relationships closely resembled those of hypothalamic extracts."( The use of corticotrophin production by adenohypophysial tissue in vitro for the detection and estimation of potential corticotrophin releasing factors.
Buckingham, JC; Hodges, JR, 1977
)
0.26
" Further increase of dosage resulted only in prolongation of duration of action (up to 48 hrs) and peak ("plateau") effect (up to 24 hrs)."( The antidiuretic action of 1-deamino-8-D-arginine vasopressin (DDAVP) in man.
Borbély, L; Fischer, J; Marosi, J; Radó, JP; Szende, L; Takó, J, 1976
)
0.26
" The results indicate: (1) aortas and portal veins from germfree rats exhibit an attenuated reactivity to angiotensin, vasopressin and epinephrine but not to KC1; (2) the dose-response curves for epinephrine and the peptides were shifted to the right concomitant with a decrease in maximum contractile tension, and (3) CaC12 dose-response curves obtained on potassium-depolarized aorta were not different from one another, whereas those obtained on portal veins from germfree animals were shifted to the right with a concomitant decrease in maximum response."( Reactivity of aorta and portal vein in germfree rats.
Altura, BM; Altura, BT; Baez, S, 1975
)
0.25
"01 microgram/kg) which had no effect on retention shifted the dose-response curve of LVP to the right."( The enhancement of retention induced by vasopressin in mice may be mediated by an activation of central nicotinic cholinergic mechanisms.
Baratti, CM; de Erausquin, GA; Faiman, CP, 1991
)
0.28
"01) lower blood levels of 1 in contrast to bolus injection of 1 without 2 under identical dosage regimens."( [The effect of the vasoconstrictor glycylpressin on the bioavailability of mitomycin C].
Czejka, M; Jäger, W; Schüller, J, 1991
)
0.28
" (1-24) ACTH, given at a dosage of 20 IU/animal, increased C and Aldo-gluc."( Excretion of electrolytes, free cortisol and aldosterone-18-oxo-glucuronide in 24-hr urines of the Mongolian gerbil (Meriones unguiculatus): effect of lysine-vasopressin and adrenocorticotrophin administration, and of changes in sodium balance.
Fenske, M, 1990
)
0.28
"In order to develop a method for selective radioprotection of the rectal mucosa, a dose-response study was carried out using triglycyl-lysine-vasopressin and lysine-vasopressin."( Determination of a suitable dosage of lysine-vasopressin and triglycyl-lysine-vasopressin, given in a gel-solution locally in the rectum of rats for possible radioprotective purposes.
Bjelkengren, G, 1990
)
0.28
" Decreasing [Mg2+]0 from the optimal concentration of 1 to 0 mM caused a 20-fold parallel rightward displacement of the oxytocin dose-response curve."( Magnesium ions and oxytocin sensitivity of the male mouse anococcygeus.
Gibson, A, 1985
)
0.27
" In order to determine an appropriate dosage of TGLVP in patients with burns, a dose-response study was undertaken."( The effect of triglycyl-lysine-vasopressin (terlipressin INN, Glypressin) on skin blood flow, measured with laser Doppler flowmetry, thermography and plethysmography. A dose-response study.
Aberg, M; Lindblom, P; Nilsson, G; Palmer, B; Vernersson, E, 1987
)
0.27
" The level and duration of antianginal and hypotensive activity were the same after single or repeated oral dosage of G-1-N to the anaesthetized rat."( [Hypotensive, antianginal action and pharmacokinetics of glyceryl-1-nitrate in rats and dogs].
Laufen, H; Leitold, M; Yeates, RA, 1986
)
0.27
" The differences in pattern and intensity of staining due to increasing the dosage rate of the in vivo vasopressin treatment, might mean that the current procedure retains preferentially either low or high affinity populations of binding sites depending on the implanted dose."( Immunocytochemically-stained vasopressin binding sites in rat brain. Ventricular application of vasopressin/Accurel in the Brattleboro rat.
Boer, GJ; Ravid, R; Swaab, DF; Van der Woude, TP, 1986
)
0.27
" VP showed a U-shaped dose-response effect."( Effects of neurohypophyseal peptide hormones on alcohol dependence and withdrawal.
Kovács, GL; Szabó, G; Telegdy, G, 1987
)
0.27
" Vasopressin dosing has also been a point of controversy."( Vasopressin therapy for upper gastrointestinal tract hemorrhage. Has its efficacy been proven?
Hussey, KP, 1985
)
0.27
" In arteries of hypertensive female subjects, responsiveness to norepinephrine (and possibly to 5-hydroxytryptamine) was increased significantly over the first half of the dose-response curve, particularly in the arteries of HT95 and HTQ subjects."( Relationship of blood pressure to the responsiveness of an isolated human artery to selected agonists and to electrical stimulation.
Wyse, DG,
)
0.13
" The dose-response relationship of LVP was non-linear."( Facilitatory effects of monoamine synthesis inhibitors on lysine-vasopressin induced changes in the exploratory behaviour pattern of male rats.
Höglund, AU; Meyerson, BJ, 1984
)
0.27
" The addition of lysine vasopressin and rat median eminence extracts (MEE) to the perfusion system concomitantly enhanced the release of ACTH-LI, beta-EP-LI, and gamma-MSH-LI, although the dose-response relationship was clear-cut only in the case of MEE."( Concomitant secretion of adrenocorticotropin, beta-endorphin, and gamma-melanotropin from perfused pituitary tumor cells of Cushing's disease: effects of lysine vasopressin, rat median eminence extracts, thyrotropin-releasing hormone, and luteinizing horm
Horii, K; Imura, H; Kageyama, N; Kuwayama, A; Nakai, Y; Nakane, T; Nakao, K; Oki, S; Shimbo, S; Tanaka, I; Watanabe, M, 1981
)
0.26
" On the 15th day, rats were anesthetized with pentobarbital, and dose-response curves to angiotensin II, lysine-vasopressin, and norepinephrine were obtained before and after intraperitoneal injection of 100 mg/kg of captopril or 1 ml of 5% glucose."( The opposing effects of chronic angiotensin-converting enzyme blockade by captopril on the responses to exogenous angiotensin II and vasopressin vs. norepinephrine in rats.
Brunner, HR; Gavras, H; Spertini, F; Waeber, B, 1981
)
0.26
" Two parameters were analyzed from the dose-response curve: pD2 and the relative contractile response compared to the maximal one induced by oxytocin."( Influence of estrogen and progesterone on the uterine sensitivity in vitro to neuropituitary hormones in the Brazilian marsupial Didelphis albiventris: comparison with lactating animals.
Calixto, SL; Ladosky, W, 1984
)
0.27
" Pressor responsiveness was evaluated acutely on the basis of dose-response curves (0."( Pressor responses of rats to vasopressin: effect of sodium, angiotensin, and catecholamines.
Brunner, HR; Burnier, M, 1983
)
0.27
" These changes were preceded by an elevation of aortic blood pressure (BP) and bradycardia, and were related to the dosage of LVP administered."( Baroreflexive suppression of heat production and fall in body temperature following peripheral administration of vasopressin in rats.
Kifune, A; Nagasaka, T; Shido, O, 1984
)
0.27
" With 2 h CS-US delay the same dosage of the peptide caused CTA impairment, manifested by weaker and faster decaying aversion to saccharin."( Specificity of the effect of desglycinamide (8-D-arginine) deaminovasopressin on short--term memory.
Bures, J; Buresová, O; Skopková, J, 1983
)
0.27
" Nevertheless, the antinociceptive action of vasopressin does not appear to be secondary to its pressor activity, since phenylephrine failed to induce an antinociceptive effect at a dosage that mimicked the pressor response to vasopressin."( Vasopressin-induced antinociception: an investigation into its physiological and hormonal basis.
Berntson, GG; Berson, BS; Kirk, WT; Torello, MW; Zipf, W, 1983
)
0.27
", as the quotient of the maximum of the cumulative dose-response curve of an agonist in a pathologically or otherwise changed target object to the maximum of the cumulative dose-response curve of the agonists in the normal target object, has been used to characterize the reaction ability for vasoconstriction of the blood vessel system of the isolated perfused hind legs of arteriosclerotic rats (pretreatment with vitamin D2) on the injection of noradrenaline (NA), 8-lysine-vasopressin (LVP), and a vasopressin preparation with an admixture of oxytocin (VA), respectively."( The term intrinsic sensitivity and its application to the vasopressor action of noradrenaline and vasopressin in arteriosclerotic rats.
Barth, T; Bekemeier, H; Hirschelmann, R, 1980
)
0.26
" Prolonged, 28 days treatment with lysine vasopressin (1 U/kg/day ip) induced hypertension and modified the dose-response curve for tremorine."( The responsiveness of M2-muscarinic receptors in the posterior hypothalamus and brain stem of vasopressin hypertensive rats.
Szadowska, A; Szmigielska, H; Szmigielski, A,
)
0.13
") and oral administration of ronidazole in sheep (n = 6) at a dosage of 5 mg/kg body weight."( Plasma ronidazole concentrations in sheep after intravenous, oral, intraruminal and intraabomasal administration.
Debackere, M; Vynckier, LJ, 1993
)
0.29
" The effects of a reduced dose (1 mg) were almost as pronounced and prolonged, suggesting that after the initial control of variceal bleeding, terlipressin therapy could be maintained for several days at low dosage to reduce the risk of early rebleeding."( Time profile of the haemodynamic effects of terlipressin in portal hypertension.
Bandi, JC; Bosch, J; Escorsell, A; Feu, F; García-Pagan, JC; Moitinho, E; Rodés, J, 1997
)
0.3
" All three peptides increased plasma insulin and glucagon concentrations, but their dose-response relationships revealed differences between them."( Effects of oxytocin, arginine-vasopressin and lysine-vasopressin on insulin and glucagon secretion in sheep.
Hyun, HS; Ito, M; Kamita, H; Mineo, H; Muto, H; Onaga, T; Yanaihara, N,
)
0.13
" Due to the limited number of patients treated so far, it is, however, difficult to draw any definite conclusions on the optimal dosage and on the occurrence of side-effects in these patients."( Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report.
De Santis, A; Giorgi, A; Laviano, A; Riggio, O; Rossi-Fanelli, F; Vaccaro, F, 2003
)
0.32
"5 mg) to a patient with severe, hyperdynamic septic shock requiring high dosage of noradrenalin."( Terlipressin increased the concentration of L-lactate in the rectal lumen in a patient with septic shock.
Jørgensen, VL; Perner, A; Waldau, T, 2004
)
0.32
" After in-patient dosage titration, outpatients' serum sodium concentrations were maintained in a narrower range in the sc group compared with the intranasal group, and the percentage of serum sodium concentrations within the normal range was greater in the sc group."( Use of subcutaneous DDAVP in infants with central diabetes insipidus.
Aijaz, N; Blanco, EJ; Blumberg, D; Lane, AH; Wilson, TA, 2006
)
0.33
"To review and assess available literature on chemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical studies, adverse events, drug interactions, and dosing and administration of terlipressin in septic shock."( Terlipressin: vasopressin analog and novel drug for septic shock.
Jennings, HR; Pesaturo, AB; Voils, SA, 2006
)
0.33
" Further studies are needed to verify safety, efficacy, and dosing of terlipressin in patients with septic shock, and its use cannot be recommended in lieu of vasopressin at this time."( Terlipressin: vasopressin analog and novel drug for septic shock.
Jennings, HR; Pesaturo, AB; Voils, SA, 2006
)
0.33
"Randomized or quasi-randomized trials evaluating vasopressin or its analogues, at any dosage or duration used as an adjunct to standard therapy (any combination of volume expansion, inotropic agents and corticosteroids) to treat refractory hypotension in neonates."( Vasopressin and its analogues for the treatment of refractory hypotension in neonates.
Fernandes, CJ; Pammi, M; Rios, D; Rossano, J; Shivanna, B, 2013
)
0.39
" Median cumulative terlipressin dosage and treatment duration were 20 mg and 5 days, respectively."( [Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome].
Ahrens, J; Galle, PR; Götz, E; Marquardt, JU; Nguyen-Tat, M; Rey, JW; Schattenberg, J; Scholz-Kreisel, P; Sivanathan, V; Wörns, MA, 2015
)
0.42
" The hemodynamics of eight patients did not improve, regardless of treatment dosage or duration."( Safety and Efficacy of Terlipressin in Pediatric Distributive Shock: A Retrospective Analysis in 20 Children.
Hofbeck, M; Kumpf, M; Michel, J; Neunhoeffer, F; Renk, H; Spiller, G, 2017
)
0.46
" Future developments in dosage and administrative techniques for terlipressin may have an important role to play in maintaining clinical efficacy whilst improving tolerability in the management of HRS."( Hepatorenal syndrome: the clinical impact of vasoactive therapy.
Colle, I; Laterre, PF, 2018
)
0.48
" Conclusions: The available evidence supports the notion that early combination therapy involving NE and TP holds promise in terms of reducing the required dosage of NE, enhancing renal perfusion, and improving microcirculation in patients diagnosed with septic shock."( TERLIPRESSIN COMBINED WITH NOREPINEPHRINE IN THE TREATMENT OF SEPTIC SHOCK: A SYSTEMATIC REVIEW.
Liang, D; Lin, L; Mao, F; Tang, Z; Xu, Y, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cyclic peptide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cellular tumor antigen p53Homo sapiens (human)Potency29.84930.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1131318Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Tyr level in presence of alpha-amylase preparation1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID1148688Antidiuretic activity in iv dosed rat1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Design of potent antagonists of the vasopressor response to arginine-vasopressin.
AID1148686Vasopressor activity in iv dosed phenoxybenzamine treated rat1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Design of potent antagonists of the vasopressor response to arginine-vasopressin.
AID1131303Oxytocic activity in isolated rat uterus strips in presence of Mg2+1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID1131304Vasodepressor activity in chicken1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID1131319Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Leu/Lys level in presence of alpha-amylase preparation1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID1131317Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Ile/Phe + DiHPe level in presence of alpha-amylase preparation1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID1131305Antidiuretic activity in iv dosed water loaded rat1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID1131320Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Gly level in presence of alpha-amylase preparation1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID1131306Vasopressor activity in phenoxybenzamine-treated rat1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1997Endocrinology, Oct, Volume: 138, Issue:10
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)1997Endocrinology, Oct, Volume: 138, Issue:10
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2000Kidney international, Oct, Volume: 58, Issue:4
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1997Endocrinology, Oct, Volume: 138, Issue:10
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,374)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990619 (45.05)18.7374
1990's222 (16.16)18.2507
2000's254 (18.49)29.6817
2010's245 (17.83)24.3611
2020's34 (2.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials173 (11.47%)5.53%
Reviews195 (12.93%)6.00%
Case Studies163 (10.81%)4.05%
Observational4 (0.27%)0.25%
Other973 (64.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]